Via PopSci
 
-----
 
 
 
  
 
 Implantable Chip The chip is about the size of an average flash memory stick.  Courtesy of MicroCHIPS Inc. 
 
  
In the future, implantable computerized dispensaries will replace 
trips to the pharmacy or doctor’s office, automatically leaching drugs 
into the blood from medical devices embedded in our bodies. These small 
wireless chips promise to reduce pain and inconvenience, and they’ll 
ensure that patients get exactly the amount of drugs they need, all at 
the push of a button. 
 
In a new study involving women with osteoporosis, a wirelessly 
controlled implantable microchip successfully delivered a daily drug 
regimen, working just as well, if not better, than a daily injection. It
 could be an elegant solution for countless people on long-term 
prescription medicines, researchers say. Patients won’t have to remember
 to take their medicine, and doctors will be able to adjust doses with a
 simple phone call or computer command. 
 
Pharmacies-on-a-chip could someday dispense a whole suite of drugs, 
at pre-programmed doses and at specific times, said Robert Langer, the 
Institute Professor at the David H. Koch Institute for Integrative 
Cancer Research at MIT, who is a co-author on the study. 
 
“It really depends on how potent the drugs are,” he said. “There are a
 number of drugs for things like multiple sclerosis, cancer, and some 
vaccines that would be potent enough.”
 
Langer and fellow MIT professor Michael Cima developed an early 
version of an implantable drug-delivery chip in the late 1990s. They 
co-founded a company called MicroCHIPS Inc., which administered the 
study being published today in Science Translational Medicine. 
The team decided to work with osteoporosis patients because the disease,
 and the drug used to treat it, presented a series of special 
opportunities, Langer said. A widely used drug called teriparatide can 
reverse bone loss in people with severe osteoporosis, but it requires a 
daily injection to work properly. This means up to 75 percent of 
patients give up on the therapy, Langer said. It’s also a very potent 
drug that requires microgram doses, making it an ideal candidate for a 
long-term dispensary implant. 
 
Getting the chips to work well required some tinkering on the part of 
the company, including the addition of a hermetic seal and drug-release 
system that can work in living tissue. The chip contains a cluster of 
tiny wells, about the size of a pinprick, which store the drug. Each 
well is sealed with an ultrathin layer of platinum and titanium, Langer 
said. At programmed times or at the patient’s command, an external 
radio-frequency device sends a signal to the chip, which applies a 
voltage to the metal film, melting it and releasing the drug. The wells 
melt one at a time.
 
“It’s like blowing a fuse, the way we’ve got it set,” Langer said. He
 said the amount of metal is near nanoscale levels and is not toxic.
 
The team also had to ensure the chips were secure and could not be 
hacked. The chips communicate via a special frequency called the  
Medical Implant Communications Service band, approved by both the FCC 
and the FDA. A bidirectional communications link between the chip and a 
receiver enables the upload of implant status information, including 
confirmation of dose delivery and battery life. A patient or doctor 
would then enter a special code to administer or change the dose, Langer
 said.
 
The research team recruited seven women in Denmark who had severe 
osteoporosis and surgically implanted the chips into their abdomens in 
January 2011. The chips stored 20 doses of the drug. The patients had 
the implants for a year, and they proved extremely popular, Langer said.
 “They didn’t think about the fact that they had it, since they didn’t 
have to have injections,” he said.
 
Ultimately, the device delivered dosages comparable to daily 
injections, and there were no negative side effects. There was no 
skipping the shot if a patient didn’t feel like visiting the doctor — 
complying with a prescription is of key importance, said Cima, the David
 H. Koch Professor of Engineering at MIT. “This avoids the compliance 
issue completely, and points to a future where you have fully automated 
drug regimens,” he said.
 
The study points out one interesting phenomenon that will inform 
future research and development on these types of implants. When you 
implant a device into a person’s body, the body forms a fibrous, 
collagen-based membrane that surrounds the foreign device. This can 
affect how well drugs can move from the device and into the body, which 
in turn affects dosage requirements and pharmaceutical potency. One of 
the aims of this study was to examine the effects of that collagen 
membrane, and the researchers found it did not have any deleterious 
effects on the drug.
 
Now that these chips have been proven to work, Langer and the others 
want to test them with other drugs and for longer dosage periods, he 
said. Because the well caps melt one at a time, the chips could be used 
to deliver different types of drugs, even those that would normally 
interact with each other if taken in shot or pill form, he said. The 
team wants to build a version with 365 doses to see how well it works. 
 
It could even be used as a long-term sensing device, he said, an 
interesting possibility of its own. Medical sensing implants can degrade
 once they’re in the body, so implants that could check for things like 
blood sugar or cancer antibodies can lose their effectiveness. But a 
chip with multiple sensors can work a lot longer — once a sensor is 
befouled, simply melt another well and expose a fresh one, Langer said.
 
The ultimate goal is to create a chip that could combine sensing and 
drug delivery — an implantable diagnostic machine that can deliver its 
own therapy.
 
“Someday it would be great to combine everything, but that will obviously take longer,” Langer said.